Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Fisher Asset Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,632,696 shares of the biotechnology company’s stock after selling 149,793 shares during the quarter. Fisher Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $19,982,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in BCRX. Farther Finance Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after buying an additional 8,109 shares during the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $81,000. State of Alaska Department of Revenue acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $90,000. MQS Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $99,000. Finally, Inceptionr LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $107,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Activity

In other news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the transaction, the insider directly owned 398,751 shares of the company’s stock, valued at $3,050,445.15. This trade represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Citizens Jmp lowered their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, November 5th. Royal Bank Of Canada lowered their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. HC Wainwright boosted their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.64.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $8.57 on Thursday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 7.14 and a beta of 0.74. The stock’s fifty day moving average is $7.20 and its two-hundred day moving average is $7.40.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $1.05. The business had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business’s revenue was up 209.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.13) EPS. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.